Breast Cancer Research and Treatment

Print ISSN
0167-6806
Electronic ISSN
1573-7217
Impact factor
4.859
Publisher
springer
URL
http://www.springerlink.com/content/0167-6806/
Usage rank
194
Article count
5904
Free count
215
Free percentage
0.036416
PDFs via platforms
Ingenta, Ovid from 2002, Springer, Gale, CSA, Metapress, Rcgp, and Proquest

  1. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.

    Breast Cancer Research and Treatment 112(1):25 (2008) PMID 18060492

    Although the epidermal growth factor receptor (EGFR) is frequently expressed in human primary breast carcinoma, the majority of breast cancer patients do not respond to treatment with EGFR tyrosine-kinase inhibitors such as gefitinib. We isolated through a stepwise dose escalation of the drug tw...
  2. Breast cancer recurrence risk in relation to antidepressant use after diagnosis.

    Breast Cancer Research and Treatment 112(1):123 (2008) PMID 18058227 PMCID PMC3519424

    While laboratory data suggest that antidepressants may promote mammary tumor growth, there has been little research investigating whether antidepressant use after breast cancer diagnosis is associated with the risk of breast cancer recurrence. We conducted a retrospective cohort study within Gro...
  3. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.

    Breast Cancer Research and Treatment 112(1):81 (2008) PMID 18058229

    The breast cancer incidence has been increasing in the south Indian women. A case (n=250)-control (n=500) study was undertaken to investigate the role of Single Nucleotide Polymorphisms (SNP's) in GSTM1 (Present/Null); GSTP1 (Ile105Val), p53 (Arg72Pro), TGFbeta1 (Leu10Pro), c-erbB2 (Ile655Val), ...
  4. Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations.

    Breast Cancer Research and Treatment 112(1):159 (2008) PMID 18058223

    The CHEK2 gene mutations I157T (c.470T>C) and IVS2+1G>A affecting the forkhead-associated domain (FHA) have been shown to increase the risk of breast cancer development in several populations. We analyzed the CHEK2 gene segment coding for FHA domain in 673 unselected breast cancer patients and 6...
  5. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.

    Breast Cancer Research and Treatment 112(1):69 (2008) PMID 18060494

    It is well established that mutations in BRCA1 and BRCA2 genes significantly increase the risk of breast and ovarian cancer. We here report 23 novel genetic variants of the BRCA1 and BRCA2 genes found in 349 cancer-prone unrelated families from Eastern Spain detected during the first 2 years of ...
  6. Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy.

    Breast Cancer Research and Treatment 112(1):189 (2008) PMID 18060577

    The aim of this study was to determine factors that predict under-evaluation of malignancy in patients diagnosed with atypical ductal hyperplasia (ADH) at ultrasound-guided core needle biopsy (CNB), and to develop a prediction algorithm for scoring the possibility of a diagnosis upgrade to malig...
  7. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

    Breast Cancer Research and Treatment 112(1):203 (2008) PMID 18158620

    A multicenter phase II study was conducted to analyze the clinical activity of the steroidal aromatase inhibitor exemestane in the neoadjuvant treatment of post-menopausal women with strongly ER- and/or PgR- positive operable breast cancer. From September 2000 to December 2003, 80 women were rec...
  8. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.

    Breast Cancer Research and Treatment 112(1):99 (2008) PMID 18064567

    Tamoxifen increases the risk of uterine corpus cancer. Since only few, mostly small, studies have examined prognosis of uterine corpus cancer following tamoxifen, we conducted a large retrospective cohort study to further investigate this. We examined histopathologic and immunohistochemical char...
  9. Nonsteroidal anti-inflammatory drugs (NSAIDs) and mammographic density.

    Breast Cancer Research and Treatment 112(1):133 (2008) PMID 18046643

    Mammographic density has been established as a strong risk factor for breast cancer while use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) has been associated with a reduction in risk of breast cancer. The hypothesis is that NSAIDs reverses the expression of prostaglandin E2, thereby reducin...
  10. Menstrual and reproductive factors in relation to mammographic density: the Study of Women's Health Across the Nation (SWAN).

    Breast Cancer Research and Treatment 112(1):165 (2008) PMID 18066689 PMCID PMC2664291

    Menstrual and reproductive factors may increase breast cancer risk through a pathway that includes increased mammographic density. We assessed whether known or suspected menstrual and reproductive breast cancer risk factors were cross-sectionally associated with mammographic density, by measurin...
  11. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.

    Breast Cancer Research and Treatment 112(1):53 (2008) PMID 18064564

    Histone deacetylase inhibitors (HDACi) are a new class of anticancer agents that cause growth arrest, differentiation and/or apoptosis in many tumor cells. As acetylation regulates the activity of the anti-apoptotic transcription factor NF-kappaB, we investigated whether the proteasome inhibitor...
  12. Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density.

    Breast Cancer Research and Treatment 112(1):109 (2008) PMID 18064566

    High breast density is one of the strongest known risk factors for developing breast cancer. Insulin-like growth factor I (IGF-I) is a strong mitogen and has been suggested to increase breast cancer risk by increasing the amount of dense tissue in the female breast. We wanted to investigate the ...
  13. Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients.

    Breast Cancer Research and Treatment 112(1):141 (2008) PMID 18058225 PMCID PMC3223859

    Inflammatory breast cancer (IBC) is a lethal form of breast cancer with unknown etiology. A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiolog...
  14. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan.

    Breast Cancer Research and Treatment 112(1):175 (2008) PMID 18075786

    The 21-gene reverse transcriptase-polymerase chain reaction assay with a patented algorithm is validated as a good predictor of prognosis and potential benefit from adjuvant chemotherapy for lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer, while its high cost raises co...
  15. Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer.

    Breast Cancer Research and Treatment 112(1):1 (2008) PMID 18060493

    Prophylactic granulocyte colony stimulating factor (GCSF) is recommended with accelerated adjuvant chemotherapy but is expensive and causes bone pain. We have reviewed a series of patients with early breast cancer treated with accelerated 2-weekly paclitaxel without routine GCSF to assess its ne...
  16. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.

    Breast Cancer Research and Treatment 112(1):41 (2008) PMID 18058224

    Beside their structural role for the cell membrane the family of sphingolipids act as effector molecules in signal transduction with links to various aspects of cancer initiation, progression and treatment response. The "sphingolipid rheostat" balances between apoptosis inducing ceramid and grow...
  17. In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.

    Breast Cancer Research and Treatment 112(1):15 (2008) PMID 18030614

    The risk of developing breast cancer is strongly correlated with the overall exposure to oestrogen and most tumours are more or less dependent on oestrogen for their growth. A great majority of breast cancers occur after menopause when the ovaries have ceased to be functional, yet breast tumours...
  18. NBS1 variant I171V and breast cancer risk.

    Breast Cancer Research and Treatment 112(1):75 (2008) PMID 18049891

    The NBS1/p95 protein has a pivotal role in the sensing and repair of chromosome breaks. A missense mutation in the NBS1 gene, I171V, has recently been associated with a ninefold increased risk of breast cancer in Polish patients. Positive associations have also been reported for leukaemia and la...
  19. The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian women.

    Breast Cancer Research and Treatment 112(1):35 (2008) PMID 18058226

    RAD51D is a homolog of the RAD51 protein, which is known to be an important component of the DNA repair pathway. A rare missense variant in the RAD51D gene, E233G (c.A>G), has been reported to be more prevalent in breast cancer cases from specific multiple-case breast cancer families, with an od...
  20. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.

    Breast Cancer Research and Treatment 112(1):89 (2008) PMID 18049890

    Estrogen exposure is involved in both breast cancer susceptibility and the prognosis in patients with breast cancer. Aromatase is involved in the production of estrogens, and altered expression of it might be associated with the prognosis. The aim of this study was to examine the effect of singl...